Thus, the observed growth-inhibitory effects of bromodomain inhibition in the luminal cells studied can be explained not only by the diminished expression of C-MYC, but also by a global reduction in the levels of transforming genes such as those exemplified by the PDZK1 and BCAS1 breast cancer oncogenes. The gene discussed is MYC; the disease is breast carcinoma.